Charles River Labs Reports Full Year Loss of $2.91 Per Share in 2025
Charles River Laboratories International (NYSE: CRL) filed its fourth quarter and fiscal year 2025 results with the SEC on February 18, 2026, revealing a challenging year marked by a significant full-year loss of $2.91 per share.
Key Numbers
The preclinical research services provider posted a net loss of $140 million for fiscal year 2025, a sharp reversal from prior profitability. This translated to a loss of $2.91 per share for the full year, according to XBRL financial data from the company's 8-K filing.
Quarterly earnings showed volatility throughout 2025. The third quarter delivered earnings of $2.65 per share with net income of $130 million, while the second quarter came in at $1.55 per share with $80 million in net income. Despite these profitable quarters, the full-year loss suggests the company faced significant headwinds, likely concentrated in the fourth quarter or potentially including one-time charges or restructuring costs.
The company's revenue trajectory from historical data shows the business had generated $1.86 billion in fiscal 2017, providing context for the scale of operations. More recent quarterly revenues from 2018 showed approximately $490 million per quarter, though current period revenue figures were not disclosed in the initial 8-K filing.
What Management Said
The 8-K filing submitted by Charles River on February 18, 2026, references an attached press release with detailed financial results and management commentary. The filing was signed by Matthew L. Daniel, Corporate Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer.
The company included standard safe harbor language in its filing, indicating that forward-looking statements are subject to various risks and uncertainties. This suggests management may have provided guidance or strategic commentary about future expectations in the full press release.
While specific management quotes were not available in the core 8-K document, the timing of the filing—coming in mid-February for a December 27 fiscal year end—follows the typical earnings release calendar for the company.
What to Watch
Several key factors warrant attention for Charles River Laboratories going forward:
Turnaround Strategy: With a full-year loss of $2.91 per share despite profitable individual quarters, investors will focus on whether the losses were driven by one-time events or reflect ongoing operational challenges. The company's ability to return to consistent profitability will be critical.
Quarterly Volatility: The wide swings in quarterly performance—from strong profits of $2.65 per share in Q3 to the overall annual loss—suggest either significant seasonality in the business or potential restructuring activities. Understanding the drivers of this volatility will be essential for forecasting future performance.
Industry Dynamics: As a provider of preclinical research services to the pharmaceutical and biotechnology industries, Charles River's results often reflect broader trends in drug development spending. Any commentary on customer demand, particularly from biotech companies that may be facing their own funding challenges, will provide important context.
Cash Flow and Balance Sheet: While the earnings showed a loss, the company's cash generation ability and balance sheet strength will determine its flexibility to navigate the current challenges. These metrics typically appear in the full 10-K filing that follows the initial 8-K announcement.
The February 18 filing represents Charles River's official quarterly report to shareholders and regulators. As a Delaware-incorporated company trading on the New York Stock Exchange under the ticker CRL, the company is required to provide timely updates on material financial results.
Investors should review the complete press release attachment referenced in the 8-K filing for additional details on segment performance, guidance updates, and management's strategic priorities for returning the company to profitability.
*Source: Charles River Laboratories International, Inc. Form 8-K filed with the Securities and Exchange Commission on February 18, 2026.*
*StockCliff Research*